Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.
Using a personalized approach that has the potential to radically improve the patient experience.
We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.
A future where a single infusion could reshape cancer care.
We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the first engineered T-cell therapy in solid tumors to help improve cancer treatment.
Goldman Sachs Cell Therapy Day
Apr 6, 2020 at 2:00 PM EDT
Speaker
Alfonso Quintas Cardama, M.D., Chief Medical Officer